{"id":768,"date":"2016-01-21T18:10:21","date_gmt":"2016-01-21T12:40:21","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=768"},"modified":"2023-06-14T12:19:00","modified_gmt":"2023-06-14T06:49:00","slug":"chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and-pipeline-analysis-2016-a-delveinsight-report","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and-pipeline-analysis-2016-a-delveinsight-report","title":{"rendered":"Chimeric Antigen Receptor T cell Immunotherapy Market Analysis and Forecast"},"content":{"rendered":"

DelveInsight, the leading market research and consulting company has added new report \u00a0 \u00a0\u201cChimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016<\/strong>\u201dto its portfolio.<\/p>\n

Reports Highlights:<\/strong><\/p>\n

\u00b7\u00a0\u00a0\u00a0 \u00a0\u00a0CAR-T cell Therapy Pipeline scenario
\n\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Collaborations & partnering deals
\n\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Current Prominent Research Areas and Key Players
\n\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Pipeline product profiles CAR-T Technologies and Targeted Antigens
\n\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Licensing opportunities
\n\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Market Drivers and Barriers<\/p>\n

Report Coverage:<\/strong><\/p>\n

40+ companies,100+\u00a0products\u00a0and 24 different technologies<\/p>\n

DelveInsight Report, \u201cChimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016<\/strong>\u201d emphasizes on the currently active CAR-T cell products in research and development. The Report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, collaborations details and deal values, technologies and targeted antigens.<\/p>\n

The Report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis. Report also describes the unmet needs covered by CAR-T cells highlighting the adverse events, which are major concerns in the market for the usage of CAR-T cells.<\/p>\n

This Report will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.<\/p>\n

DelveInsight is offering the Report at a price of USD 2,450 as a single user license, USD 4,900 as a site license and USD 7,350 as a Global\/Enterprise License.<\/p>\n

For more information on Pipeline Insight Reports, email at info@delveInsight.com<\/a><\/p>\n

Contact Us:<\/strong><\/p>\n

DelveInsight Business Research<\/p>\n

New Delhi-110075, India<\/p>\n

Phone:<\/strong> +91-11-45689769, +91 9650213330<\/p>\n

About Us<\/strong><\/p>\n

DelveInsight is a leading Business Consulting and Market Research Firm.\u00a0 We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight, the leading market research and consulting company has added new report \u00a0 \u00a0\u201cChimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016\u201dto its portfolio. Reports Highlights: \u00b7\u00a0\u00a0\u00a0 \u00a0\u00a0CAR-T cell Therapy Pipeline scenario \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Collaborations & partnering deals \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Current Prominent Research Areas and Key Players \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Pipeline product profiles CAR-T Technologies and Targeted […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[134,146,173,180,204,356,386,479],"industry":[17225],"therapeutic_areas":[17231,17228,17234],"class_list":["post-768","post","type-post","status-publish","format-standard","hentry","category-articles","tag-business-consultant","tag-cart","tag-collaborations","tag-competitive-landscape","tag-delveinsight","tag-licensing-opportunities","tag-market-trends","tag-pipeline-coverage","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nChimeric Antigen Receptor T cell Immunotherapy Market Outlook<\/title>\n<meta name=\"description\" content=\"DelveInsight Report, \u201cChimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016\u201d emphasizes..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and-pipeline-analysis-2016-a-delveinsight-report\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chimeric Antigen Receptor T cell Immunotherapy Market Outlook\" \/>\n<meta property=\"og:description\" content=\"DelveInsight Report, \u201cChimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016\u201d emphasizes..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and-pipeline-analysis-2016-a-delveinsight-report\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-01-21T12:40:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T06:49:00+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chimeric Antigen Receptor T cell Immunotherapy Market Outlook","description":"DelveInsight Report, \u201cChimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016\u201d emphasizes..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and-pipeline-analysis-2016-a-delveinsight-report","og_locale":"en_US","og_type":"article","og_title":"Chimeric Antigen Receptor T cell Immunotherapy Market Outlook","og_description":"DelveInsight Report, \u201cChimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016\u201d emphasizes..","og_url":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and-pipeline-analysis-2016-a-delveinsight-report","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-01-21T12:40:21+00:00","article_modified_time":"2023-06-14T06:49:00+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and-pipeline-analysis-2016-a-delveinsight-report","url":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and-pipeline-analysis-2016-a-delveinsight-report","name":"Chimeric Antigen Receptor T cell Immunotherapy Market Outlook","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2016-01-21T12:40:21+00:00","dateModified":"2023-06-14T06:49:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"DelveInsight Report, \u201cChimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016\u201d emphasizes..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and-pipeline-analysis-2016-a-delveinsight-report"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CART<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Competitive landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">licensing opportunities<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">market trends<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline coverage<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">CART<\/span>","<span class=\"advgb-post-tax-term\">collaborations<\/span>","<span class=\"advgb-post-tax-term\">Competitive landscape<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">licensing opportunities<\/span>","<span class=\"advgb-post-tax-term\">market trends<\/span>","<span class=\"advgb-post-tax-term\">Pipeline coverage<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jan 21, 2016","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Jan 21, 2016 6:10 pm","modified":"Updated on Jun 14, 2023 12:19 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=768"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/768\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=768"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=768"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}